Cargando…

A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) is a major cause of cancer-related death. It is a highly vascular tumour with multiple angiogenic factors, most importantly vascular endothelial growth factor (VEGF), involved in HCC progression. Tivozanib is an oral inhibitor of VEGFR-1/2/3 with promising...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fountzilas, Christos, Gupta, Medhavi, Lee, Sunyoung, Krishnamurthi, Smitha, Estfan, Bassam, Wang, Katy, Attwood, Kristopher, Wilton, John, Bies, Robert, Bshara, Wiam, Iyer, Renuka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109127/ https://www.ncbi.nlm.nih.gov/pubmed/32037403 http://dx.doi.org/10.1038/s41416-020-0737-6

Ejemplares similares

Evaluation of the serotonin pathway as a biomarker in cholangiocarcinoma
por: Fountzilas, Christos, et al.
Publicado: (2023)

Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis
por: Oh, Hyunwoo, et al.
Publicado: (2020)

Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications
por: Gupta, Medhavi, et al.
Publicado: (2019)

Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients
por: Kalathil, Suresh Gopi, et al.
Publicado: (2020)

Tivozanib for hepatocellular carcinoma: not likely a new option
por: Estrade, Florian, et al.
Publicado: (2020)

Hepatocellular Carcinoma: Special Issue Highlights
por: Gupta, Medhavi, et al.
Publicado: (2020)

Tivozanib in the treatment of renal cell carcinoma
por: Hepgur, Mehmet, et al.
Publicado: (2013)

Comparison of characteristics and outcomes of young‐onset versus average onset pancreatico‐biliary adenocarcinoma
por: Jayakrishnan, Thejus, et al.
Publicado: (2023)

Exploring the role of survivin in neuroendocrine neoplasms
por: Hanif, Ahmad, et al.
Publicado: (2020)

Milestones for development of tivozanib for kidney cancer therapy
por: Crescentini, Robert, et al.
Publicado: (2012)

Prognostic value of histone chaperone FACT subunits expression in breast cancer
por: Attwood, Kristopher, et al.
Publicado: (2017)

Tivozanib: a novel VGFR inhibitor for kidney cancer
por: Boyle, Helen
Publicado: (2013)

Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives
por: Rodenburg, RJ, et al.
Publicado: (2019)

Immunotherapy Plus Locoregional Therapy Leading to Curative-Intent Hepatectomy in HCC: Proof of Concept Producing Durable Survival Benefits Detectable with Liquid Biopsy
por: Raj, Roma, et al.
Publicado: (2023)

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
por: Cowey, C Lance
Publicado: (2013)

Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma
por: Yalcin, Suayib, et al.
Publicado: (2019)

Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma
por: Sakellakis, Minas, et al.
Publicado: (2023)

Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based Test
por: Mahalingam, Devalingam, et al.
Publicado: (2021)

Anti PD-1/Anti PDL-1 Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Meta-Analysis of Phase 2/3 Randomized Controlled Trials
por: Parmar, Kanak, et al.
Publicado: (2022)

Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?
por: Mihály, Zsuzsanna, et al.
Publicado: (2012)

Tivozanib in renal cell carcinoma: a new approach to previously treated disease
por: Salgia, Nicholas J., et al.
Publicado: (2020)

Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model
por: Alanazi, Wael A., et al.
Publicado: (2023)

Is Chemoembolisation of Value in Inoperable Primary Hepatocellular Carcinoma
por: Raoul, Jean-Luc
Publicado: (1998)

Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer?
por: Gross-Goupil, Marine, et al.
Publicado: (2012)

Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature
por: Caquelin, Laura, et al.
Publicado: (2022)

Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
por: Westerman, Mary E., et al.
Publicado: (2020)

Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma
por: Lee, Victor Ho-Fun, et al.
Publicado: (2015)

Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells
por: Momeny, Majid, et al.
Publicado: (2017)

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3
por: Meza, Luis, et al.
Publicado: (2022)

Inoperable Cancer
Publicado: (1901)

Left sided breast cancer is associated with aggressive biology and worse outcomes than right sided breast cancer
por: Abdou, Yara, et al.
Publicado: (2022)

Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma
por: Zhou, Kehua, et al.
Publicado: (2019)

Racial differences in CD8(+) T cell infiltration in breast tumors from Black and White women
por: Abdou, Yara, et al.
Publicado: (2020)

Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells
por: Momeny, Majid, et al.
Publicado: (2017)

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
por: Molina, Ana M., et al.
Publicado: (2018)

NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors
por: Villa, E, et al.
Publicado: (2001)

Combination therapy of transcatheter arterial chemoembolization with axitinib for the treatment of inoperable hepatocellular carcinoma
por: Nouso, Kazuhiro, et al.
Publicado: (2020)

Thyroidectomy in Inoperable Cancer
Publicado: (1909)

Cannot write session to /tmp/vufind_sessions/sess_6hd9emcci5njn743s2hs531v4h